Table 3 |
||||
|
Extrinsic factor-induced models of Sjögren's syndrome |
||||
|
Strain |
Extrinsic factor |
SS-like disease manifestations |
Remarks |
Reference |
|
|
||||
|
BALB/c |
Ro amino acids 480 to 494 |
SG infl., ↓ SG function, anti-Ro and anti-La |
Low disease penetrance rate |
[136] |
|
Ro amino acids 274 to 290 |
SG infl., ↓ SG function, anti-Ro and anti-La |
Low disease penetrance rate |
[136] |
|
|
C57BL/6-Rag1-/- |
Six peptides from M3R |
SG and LG infl., ↓ SG function |
Splenocytes from vaccinated M3r-/- mice |
[140] |
|
PL/J |
CAII |
SG infl. |
Inflammatory lesions in multiple organs |
[142] |
|
C57BL/6-gld//gld |
MCMV |
SG infl., anti-Ro and anti-La |
Incomplete clearance of the MCMV |
[144] |
|
|
||||
|
Selection of murine strains in which Sjögren's syndrome (SS)-like disease manifestations develop after the administration of specific extrinsic factors. ↑, increased; ↓, decreased; CAII, carbonic anhydrase II; infl., inflammation; LG, lacrimal gland; M3R, muscarinic acetylcholine type-3 receptor; MCMV, murine cytomegalovirus; SG, salivary gland. |
||||
|
Delaleu et al. Arthritis Research & Therapy 2011 13:217 doi:10.1186/ar3313 |
||||